Treatment options for chronic myeloid leukemia often include targeted therapies. Treatment plans and their effectiveness may depend on the phase of the condition.
Chronic myeloid leukemia (CML) is a slow-growing type of blood cancer that can affect white and red blood cells and platelets. It occurs in about 15% of adults who receive a leukemia diagnosis.
CML has three phases: chronic, accelerated, and blast.
The different phases can have an impact on a persons overall prognosis and how a doctor and the person approach the treatment plan.
This article discusses common treatments for CML and the differences between the phases of the condition.
The chronic phase is the earliest stage of CML.
In this phase, the cancer grows and spreads most slowly, and people typically experience few or no symptoms.
Moreover, during this stage of CML, people have less than 10% blast cells, which are cancerous immature white blood cells.
Most people receive a diagnosis of CML in the chronic phase.
During the chronic phase, the first line of treatment is tyrosine kinase inhibitors (TKIs). A doctor may try one or more TKIs, such as:
If a specific TKI is ineffective, a doctor may change a persons dose or use a different medication. On rare occasions, a doctor may recommend a bone marrow transplant.
During treatment, a doctor will need to check the progress regularly. To do this, they will need to draw blood and check for levels of BCR-ABL, a cancer-causing gene, every 36 months. A persons doctor should review the results of the tests with the person.
A 2017 long-term study found that the 10-year survival rate of people who received a diagnosis of chronic phase CML was about 83% when they took imatinib.
The American Cancer Society states that about 70% of people have a complete response to TKI treatments within the first year.
If the first treatment does not prove effective, a doctor may consider the following:
Treatment following a stem cell transplant can vary based on the response a persons body has to the transplant.
If the persons body does not reject the transplant, a doctor may try to have the immune system attack the cancer cells by either reducing the amount of immunosuppressors or introducing donor cells.
The second phase of CML is the accelerated phase, during which blast counts are higher, and symptoms are likely to develop.
In addition, during this stage, a person has increased cancer activity.
According to the American Cancer Society, a doctor will often diagnose the accelerated phase if one or more of the following occur:
A person with accelerated phase CML is also more likely to experience symptoms such as:
The American Cancer Society states treatment for the accelerated phase will be similar to that for the chronic phase. The main difference is that in the second phase of CML, long-term success with treatment is less likely.
Treatment options, which will depend on what doctors have already used, may include:
It is difficult to determine the life expectancy of a person who receives a diagnosis of CML in the accelerated phase.
The American Cancer Society indicates a person is less likely to have a long-term response to the treatment.
However, researchers are studying new therapies, which may help prolong the life expectancy of people with a diagnosis of accelerated CML.
The blast phase is the most advanced stage of CML.
People with a blast phase CML diagnosis have at least 20% blast cells in their blood. At this stage, the cancer has also spread beyond the blood into organs or other tissues.
Additionally, a person will likely experience fever, small appetite, and weight loss.
Treatment will vary between people depending on the cancer and the type of treatment a person has already undergone.
A cure for CML in the blast phase is unlikely. That is why doctors will possibly recommend medication and therapy to help a person feel better and relieve their symptoms.
According to the American Cancer Society, a doctor may recommend newer TKIs, such as bosutinib, dasatinib, or nilotinib. Chemotherapy drugs may be effective.
If treatment is successful, a doctor may recommend a stem cell transplant.
With newer therapies, the exact survival rate of people with a blast phase CML diagnosis is not clear.
People with blast phase CML are less likely to respond well to treatment and to recover from their condition than people with a chronic phase CML.
A 2018 study reports that people with CML whose cancer cells have the T315I mutation are less likely to respond to both older and newer TKIs.
As a result, doctors will likely recommend a different strategy, such as:
CML is a type of cancer. There are several potential therapies a doctor may recommend a person undergo to treat the cancer, slow its growth, or improve a persons quality of life.
Below, we describe some of the most common approaches.
Targeted therapies are medications that identify and attack cancer cells based on certain markers.
CML contains BCR-ABL, a gene that is not present in healthy cells. The gene causes the production of BCR-ABL protein, which is a type of tyrosine kinase. Targeted therapies for CML contain TKIs that stop the growth and reproduction of cancer cells with the protein.
According to the American Cancer Society, TKIs are a frequently used treatment option in the chronic phase of CML. However, doctors may also use them in later phases of the condition.
Interferon therapy is the most common treatment for CML.
It recreates interferons, a substance the immune system produces naturally. The therapy helps prevent the growth and division of cancer cells.
Chemotherapy, or chemo, which doctors use to treat many different types of cancer, slows or stops the growth and division of cancer cells.
It may cure the cancer, reduce the likelihood of it returning, or slow or stop its growth. It may also improve symptoms.
Chemotherapy used to be the primary treatment for CML. However, TKIs are now the first line of treatment.
Doctors will typically only recommend chemotherapy if a person does not respond well to TKIs or is undergoing a stem cell transplant.
Radiation therapy uses high doses of waves of energy to destroy cancer cells. The damaged cancer cells can no longer reproduce, and die as a result.
The National Cancer Institute states that it can take several weeks of treatment to damage cancer cells enough for them to start dying off. It could then take a few weeks or months for the cells to die off completely.
However, according to the American Cancer Society, radiation is not a common treatment for CML.
Doctors may use it to reduce the size of the spleen if the cancer has spread there, to treat bone pain resulting from bone damage. They may also use it during stem cell transplant throughout the body.
Surgery is not a typical treatment option for CML. That is because the cancer can spread throughout a persons bone marrow and other organs.
Doctors will typically only recommend surgery to remove the spleen if the cancer has affected it.
A stem cell transplant involves destroying cancer cells and some healthy cells in the bone marrow, where the leukemia starts.
Once the cancer is destroyed, a doctor replaces the cells with healthy bone marrow cells that a donor provided. Usually, doctors offer this treatment option to younger people who have a matched tissue donor.
While this is the only treatment that can cure CML, it has several associated risks, including infection and graft-versus-host disease.
A person with a diagnosed CML may wish to try alternative or complementary therapies to help alleviate symptoms. They should seek guidance from a doctor to find the most suitable therapies.
According to a 2016 study, traditional Chinese herbal medicine may be effective in managing CML when people use it in conjunction with Gleevec.
However, a person should speak with their doctor about this type of treatment before finding a licensed practitioner of traditional Chinese medicine.
Another study looked at several different herbs and fruits for the treatment of leukemia. Although the study indicates more research is necessary, it reports positive results when using herbs such as ginger, garlic, and carrots.
CML is a slow-growing type of leukemia that develops in the bone marrow.
Experts distinguish three phases of the condition: chronic, accelerated, and blast. Treatments across the three phases are often similar and involve using TKIs.
A person can work with their doctor to create the best treatment options for them. If the treatment is ineffective, a doctor may recommend other therapies to achieve remission or improve a persons quality of life.
Originally posted here:
Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today
- Catapulting Stem Cell Research into the Future: Innovation and Global Impact at ISSCR 2025 in Hong Kong - geneonline - January 9th, 2025
- Stem cell transplant research breakthrough gives hope to those with blood cancer - University of Birmingham - November 29th, 2024
- Accelerating stem cell research - The University of British Columbia - November 22nd, 2024
- ISSCR Guidelines for Stem Cell Research and Clinical ... - PubMed - October 18th, 2024
- Induced pluripotent stem cell-derived mesenchymal stem cells: whether ... - October 18th, 2024
- AIIMS Bathinda Makes Breakthrough in Stem Cell Therapy Research for Heart Ailments - Elets - October 15th, 2024
- Manufactured stem cells could help to treat blood cancers in the future - October 8th, 2024
- New Facility Will Expand UC Merced's Groundbreaking Stem Cell Research - University of California, Merced - October 2nd, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 26th, 2024
- Scientists in Madison studying synthetic materials with applications in stem cell research - Wisbusiness.com - September 26th, 2024
- OpRegen (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium -... - September 26th, 2024
- Stem Cell Therapy Research: Creative Biolabs Advances iPSC-Derived Macrophage Solutions - openPR - September 20th, 2024
- Stem Cell Research About Stem Cells - September 20th, 2024
- $34 million for research into stem cell therapies for osteoarthritis and other conditions - BioMelbourne Network - September 18th, 2024
- $55 million for stem cell therapies, data infrastructure and research into rheumatoid arthritis - Department of Health - September 10th, 2024
- Discoveries from human stem cell research in space that are relevant to advancing cellular therapies on Earth - Nature.com - August 24th, 2024
- Stem Cell Therapy Market is expected to generate a revenue of USD 31.41 Billion by 2030, Globally, at 13.95% CAGR: Verified Market Research -... - August 16th, 2024
- Stem Cell Therapy Market is expected to generate a revenue of USD 31.41 Billion by 2030, Globally, at 13.95% CAGR: Verified Market Research - PR... - August 12th, 2024
- Advanced Parkinsons in a dish model accelerates research Harvard ... - August 10th, 2024
- Understanding Stem Cell Research | UCLA BSCRC - August 6th, 2024
- TREEFROG THERAPEUTICS PARTICIPATES IN AN INNOVATION SHOWCASE & POSTER SESSION AT THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) ANNUAL... - July 12th, 2024
- Familiar face to take over as CEO of California's stem cell research funding agency - The Business Journals - July 12th, 2024
- Factor Bioscience to Deliver Six Presentations at the International Society for Stem Cell Research (ISSCR) 2024 Annual Meeting - The Malaysian Reserve - July 12th, 2024
- Research harnesses machine learning and imaging to give insight into stem cell behavior - Medical Xpress - July 5th, 2024
- Stem Cell Research Uncovers Clues to Tissue Repair That Could Help Heal the Uterus and More - Yale School of Medicine - May 29th, 2024
- Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human ... - PR Newswire - May 27th, 2024
- Unparalleled Research on Adipose Tissue-Derived Stem Cell Therapy Market With Current and Future Growth ... - openPR - May 15th, 2024
- 100 plus years of stem cell research20 years of ISSCR - PMC - March 26th, 2024
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 18th, 2024
- Stem cell research project to launch into space - Fox Weather - January 24th, 2024
- Breakthrough in cancer research opening up stem cell therapy to more people. How you can get involved - 69News WFMZ-TV - January 20th, 2024
- Stem Cell Research Heading to the ISS on Axiom Mission 3 - ISS National Lab - January 18th, 2024
- No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - The Dispatch - January 12th, 2024
- Applications are open for the Maryland Stem Cell Research Fund - Technical.ly - January 4th, 2024
- Global Stem Cell Therapy Market to Reach USD 928.6 Million by 2031: Says Allied Market Research - Yahoo Finance - November 19th, 2023
- Current state of stem cell-based therapies: an overview - PMC - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance Regenrative Medicine - Yahoo Finance - November 3rd, 2023
- Research Fellow (Aging and Cancer Stem Cell Laboratory ... - Times Higher Education - October 15th, 2023
- Qkine Collaborates with the Cambridge Stem Cell Institute to Facilitate Same-Day Access to Key Research Products for Researchers at the Cambridge... - September 27th, 2023
- Stem cells: a comprehensive review of origins and emerging clinical ... - September 25th, 2023
- Stem Cell Research and Communicating Science | GBH - GBH News - September 20th, 2023
- Stem cell research reveals the earliest stages of a human life - SBS News - September 10th, 2023
- Stem Cell Therapy Market Size 2023 | Innovative Research Methodologies with Emerging Trends and Opportuni - Benzinga - September 10th, 2023
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research, Current Trends, Key Industry Play - Benzinga - September 8th, 2023
- Stem Cell Therapy Market 2023 Business Statistics and Research ... - The Knox Student - August 28th, 2023
- Autologous Stem Cell Based Therapies Market Analysis, Research ... - Chatfield News-Record - July 19th, 2023
- Global Stem Cell Market Projected to Reach $14 Bn by 2028: Ken Research - Yahoo Finance - July 11th, 2023
- Theradaptive Awarded Manufacturing Assistance Grant by the Maryland Stem Cell Research Fund - Benzinga - July 10th, 2023
- Bionano Announces Presentation of OGM Utility Across Stem Cell Therapy Applications at the International Society for Stem Cell Research (ISSCR) Annual... - June 19th, 2023
- Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023... - June 17th, 2023
- Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments - Yahoo... - June 17th, 2023
- Lung and heart stem cell research paves way for new COVID-19 treatments - Medical Xpress - June 14th, 2023
- Toxicology PhD student cultivating giant leaps in stem cell research ... - June 4th, 2023
- Harvard Stem Cell Institute (HSCI) - May 26th, 2023
- Findings may lead to improved insulin-secreting cells derived from stem ... - May 26th, 2023
- Cell Press: Stem Cell Reports - May 26th, 2023
- Stem cell research could enable blood to be made in other parts of the body - Medical Xpress - May 26th, 2023
- Construction of myocardial patch with mesenchymal stem cells and poly ... - May 22nd, 2023
- Cedars-Sinai to Send Stem Cells to the Space Station to Aid in the ... - May 22nd, 2023
- researchers expand human blood stem cells | Institute for Stem Cell ... - May 22nd, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Exclusive Research Report on Msenchymal Stem Cell and Exosome Diagnostics and Therapies Market to Witness Comp - openPR - May 17th, 2023
- The Future of Stem Cell Research: Master of Science in ... - The Daily | Case Western Reserve University - May 10th, 2023
- Exclusive Research Report on Stem Cell Therapy for Diabetes and ... - Digital Journal - May 9th, 2023
- Aging melanocyte stem cells and gray hair | National Institutes of ... - May 5th, 2023
- Mouse hair turns gray when certain stem cells get stuck - May 5th, 2023
- Science-First Skincare Company Michal Morrison Secures Exclusive World-Wide License of Proprietary STEM6 Molecule, Supported by Over 25 Years of... - May 5th, 2023
- BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansi - Benzinga - May 3rd, 2023
- Hair turning gray? Study finds a stem cell 'glitch' may be the cause - May 1st, 2023
- Elevai Labs Announces Research Grant Award and Partnership to Better Characterize the 'Payload' of ELEVAI's Stem Cell-derived Exosomes - Yahoo Finance - April 27th, 2023
- Why does hair turn gray? A new study says 'stuck' stem cells may ... - NPR - April 27th, 2023
- Study advances understanding of how melanocyte stem cells work to color ... - April 21st, 2023
- Stem cell research and therapy legislation to be replaced, says ... - Bahamas Tribune - April 21st, 2023
- Stem Cell Research (journal) - Wikipedia - April 21st, 2023
- Scientists Are About to Try to Create Stem Cells in Space - April 21st, 2023
- Stem Cell Research & Therapy | Articles - BioMed Central - April 16th, 2023
- Stem Cell Junk Yards Reveal a New Clue About Aging | WIRED - April 16th, 2023
- Global Stem Cells Market Research Report 2023: Implications - April 16th, 2023
- Stem cell research can help people with hard- | EurekAlert! - April 16th, 2023
- University Of Edinburgh's stem cell research gets funding boost - India Education Diary - April 14th, 2023
Recent Comments